Prolonged Progression-Free Survival in a Patient with Highly Pretreated Recurrent Ovarian Cancer after Developing Multisystem Immune-Related Adverse Events: A Case Report and Literature Review

作者：Minling Liu, Shuo Fang, Huiru Dai, Tingwei Li, Chunyan Guo, Wei Wang · 发表于：Case Reports in Oncology · 年份：2025 · DOI：10.1159/000546423 · 被引用次数：1 · 研究领域：Cancer Immunotherapy and Biomarkers、PARP inhibition in cancer therapy、Colorectal and Anal Carcinomas

Introduction: The development of immune-related adverse events (irAEs) has been associated with improved survival from various solid tumors. Given that immunotherapy has not been widely used in ovarian cancer and has only been applied to patients with high tumor mutational burden or microsatellite instability, studies exploring the effects of irAEs on ovarian cancer have been limited. Case Presentation: A 47-year-old woman was diagnosed with International Federation of Gynecology and Obstetrics stage III ovarian cancer in 2013. Between 2013 and 2021, she underwent palliative chemotherapy comprising paclitaxel liposomes, cisplatin/nedaplatin, S-1/raltitrexed, irinotecan, doxorubicin, vinorebine, toripalimab, apatinib, gemcitabine, oxaliplatin, and capecitabine, as well as two debulking surgeries. From November 2021, she received six cycles of tislelizumab (a PD-1 inhibitor), paclitaxel (albumin-bound), and carboplatin, to which a partial response was observed according to the Response Evaluation Criteria in Solid Tumors. From May 2022, the patient was switched to maintenance therapy with tislelizumab plus olaparib. However, all antitumor treatments were discontinued from April 2023 due to multiple irAEs, including hypothyroidism, adrenal insufficiency, and pneumonitis, with the tumor remaining stable until November 2023. Progression-free survival (PFS) was approximately 24 months with tislelizumab-containing therapy but was 18 months with tislelizumab/olaparib maintenance ther...